Natalizumab improves ambulation in relapsing−remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM

Publisher： John Wiley & Sons Inc

E-ISSN： 1468-1331|22|3|570-577

ISSN： 1351-5101

Source： EUROPEAN JOURNAL OF NEUROLOGY, Vol.22, Iss.3, 2015-03, pp. : 570-577

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis

By  

ANNALS OF NEUROLOGY, Vol. 77, Iss. 3, 2015-03 ,pp. : 425-435

John Wiley & Sons Inc

Access to resources Recommend Favorite

Emerging Therapies in Relapsing-Remitting Multiple Sclerosis

By  

Reviews on Recent Clinical Trials, Vol. 5, Iss. 3, 2010-09 ,pp. : 179-188

Bentham Science Publishers

Access to resources Recommend Favorite

PK and PD of peginterferon beta‐1a in multiple sclerosis patients

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 79, Iss. 3, 2015-03 ,pp. : 514-522

John Wiley & Sons Inc

Access to resources Recommend Favorite

Health perceptions and clinical characteristics of relapsing-remitting multiple sclerosis patients: baseline data from an international clinical trial

By Robinson D.   Zhao N.   Gathany T.   Kim L.-L.   Cella D.   Revicki D.  

Current Medical Research and Opinion, Vol. 25, Iss. 5, 2009-05 ,pp. : 1121-1130

Informa Healthcare

Access to resources Recommend Favorite

Teriflunomide for relapsing remitting multiple sclerosis

By  

PRESCRIBER, Vol. 26, Iss. 18, 2015-09 ,pp. : 11-14

John Wiley & Sons Inc

Access to resources Recommend Favorite